UBE3A stabilization of β-catenin preserves synaptic proteins essential for motor and cognitive functions in Angelman Syndrome.

This is a preclinical study using mice and cell cultures; results may not translate to humans. Lithium impaired contextual fear memory in wild-type mice, raising safety concerns about cognitive side effects in unaffected individuals or potentially in the target population depending on dosage and timing. The study used a specific mouse model (maternal deletion); other genetic causes of Angelman syndrome were not tested. Long-term safety and optimal dosing were not established. The mechanism of how UBE3A directly regulates beta-catenin stability requires further elucidation beyond the observed correlation and rescue.

The paper is supported by non-U.S. government funding. No specific conflicts of interest involving commercial entities selling the tested interventions were declared in the provided text.

Do not interpret the improvement in mouse behavior as evidence that lithium is a safe or effective treatment for Angelman syndrome in humans. The same treatment worsened memory in healthy control mice, and human data on lithium safety in children with intellectual disability remains sparse and inconclusive.